
## Renu K Virk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3824621/publications.pdf Version: 2024-02-01



**DENILK VIDE** 

#	Article	IF	CITATIONS
1	A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. Nature Cancer, 2020, 1, 1082-1096.	13.2	49
2	Cooperation of loss of <i>NKX3.1</i> and inflammation in prostate cancer initiation. DMM Disease Models and Mechanisms, 2018, 11, .	2.4	30
3	NKX3.1 Localization to Mitochondria Suppresses Prostate Cancer Initiation. Cancer Discovery, 2021, 11, 2316-2333.	9.4	25
4	A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder. Journal of Urology, 2020, 204, 247-253.	0.4	23
5	Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5î±-reductase Inhibition. European Urology, 2017, 72, 499-506.	1.9	16
6	RAD9A promotes metastatic phenotypes through transcriptional regulation of anterior gradient 2 (AGR2). Carcinogenesis, 2019, 40, 164-172.	2.8	15
7	Impact of COVIDâ€19 pandemic on functioning of cytopathology laboratory: Experience and perspective from an academic centre in New York. Cytopathology, 2021, 32, 304-311.	0.7	14
8	Targeting MEK5 impairs nonhomologous end-joining repair and sensitizes prostate cancer to DNA damaging agents. Oncogene, 2020, 39, 2467-2477.	5.9	11
9	The effect of tumor grade heterogeneity on recurrence in non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 60.e11-60.e16.	1.6	7
10	FOXP1 and NDRG1 act differentially as downstream effectors of RAD9-mediated prostate cancer cell functions. Cellular Signalling, 2021, 86, 110091.	3.6	6
11	Bladder Preservation for Patients With Bladder Paragangliomas: Case Series and Review of the Literature. Urology, 2020, 143, 194-205.	1.0	4
12	<scp>BIAâ€ALCL</scp> diagnosis on <scp>CytoLyt</scp> fixed <scp>ThinPrep</scp> , cell block and immunohistochemistry. Diagnostic Cytopathology, 2022, 50, E1-E5.	1.0	3
13	The Significance of ASC-H and LSIL Dual Interpretation with Risk Stratification: One Institution Experience. Journal of the American Society of Cytopathology, 2021, 10, 565-570.	0.5	2